Differential Genomic and Proteomic Signatures In Cord Blood (CB) Vs Peripheral Blood (PB) CD56+Dim NK Cells: Over Expression of CD34 In CB Vs PB CD56+Dim NK Cells

Abstract 2781 Umbilical cord blood (UCB) is a viable alternative source of allogeneic hematopoietic stem cells for the treatment of both malignant and non-malignant disease (Cairo et al BBMT 2008). UCB transplantation (UCBT) is known to be associated with decrease severe acute graft-versus-host dise...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 116; no. 21; p. 2781
Main Authors Day, Nancy S, Shereck, Evan, Ayello, Janet, McGuinn, Catherine, Satwani, Prakash, Atallah, Juliana, van de Ven, Carmella, Wapner, Ronald J, Lim, Megan S., Cairo, Mitchell S.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 19.11.2010
Online AccessGet full text

Cover

Loading…
Abstract Abstract 2781 Umbilical cord blood (UCB) is a viable alternative source of allogeneic hematopoietic stem cells for the treatment of both malignant and non-malignant disease (Cairo et al BBMT 2008). UCB transplantation (UCBT) is known to be associated with decrease severe acute graft-versus-host disease (GvHD) compared to unrelated bone marrow (BM) and peripheral blood (PB) transplantation; however, it is associated with delayed hematopoietic and immune reconstitution (Szabolcs/Cairo et al Seminars in Hematology 2010). NK cells play important roles in both innate and adaptive immunity and are characterized as a CD56+ cell population. NK cell recovery is prompt by 2 months after hematopoietic stem cell transplantation (HSCT), while T-cell (after at least 9 mo HSCT) and B-cell (after 3 to 4 mo HSCT) reconstitutions are gradual and delayed. CD56+dim cells are primarily cytotoxic and make up 90% of PB NK populations (Shereck/Cairo PBC 2007). We previously demonstrated the ability to ex-vivo expand CB MNC into various phenotypes of CD56+dim and CD56+bright NK cells (totally 60%) and NKT cells (40%) with profound in vitro and in vivo cytotoxicity against hematological malignancies (Ayello/Cairo BBMT 2006 & Exp. Hematology 2009). Proteomic studies from our group demonstrated differential protein expression including ↑NKG2A, ↓IP3R type 3, ↓MAPKAPK5, and ↑NOTCH 2 in CB vs PB CD56+dim (Shereck/Cairo, ASH 2007; Shereck/Day/Cairo, ASBMT 2009). In these studies, we sought to determine the similarity or differences in genetic signatures in CB vs APB CD56+dim NK cells. CB MNCs were isolated on a ficoll gradient and NK CD56+16+dim cells isolated using a 2-step magnetic activated cell separation (MACS) process via a standard kit (Miltenyi Biotec). Enrichment was at least 94%. Isolated RNA from CB and PB CD56+dim cells were subjected to microarray studies (Affymetrix, U133A_2) as we have previously described (Jiang/Cairo et al J Immunol 2004). Data were analyzed by Agilent GeneSpring and Ingenuity pathway analyses. Welch test were used to perform statistical analysis and fold change of < 1.5 and values of p<0.05 were considered to be significant. Two-color ECL Plex fluorescence Western blotting (WB) was preformed to validate the proteomic data. Protein samples were separated using SDS-PAGE followed by transblotting. WB membranes were then incubated with target and control (GAPDH) primary antibodies. After rinse and wash, the membranes were further incubated with CY5 and CY3 conjugated secondary antibodies. The membranes were scanned with TYPHOON by green (532 laser and 580 filter) and red (633 laser and 670 filter) setting for CY3 and CY5, respectively, and then observed and quantified using ImageQuant. CB vs PB CD56+dim cells significantly altered expressed 796 genes, in which 486 genes were over expressed, at the genomic level including: pro-apoptotic genes: CASP10 (3.1F), TNFSF11 (4.7F), CDC2 (3.0F), BCL2L1 (4.3F), NOTCH2 (1.5F); and cell development: PBX1 (7.6F), IL1RN (5.1F), CD24 (5.3F), CD34 (3.5F), CD55 (2.1F), CCL13 (2.2F). Conversely, there was significant under expression of NF1 (5.1F), MAP2K3 (1.7F), PIK3CD (2.1F), BAX (2.9F), and JUN (2.2F). Our WB results indicate that NOTCH2 (2.4F) and PBX1 (2.2F) proteins are increased in CB vs PB CD56+dim NK cells, consistent with our proteomic results. These results suggest that CB vs PB CD56+dim NK are more prone to undergo programmed cell death (apoptosis) secondary to over expression of numerous pro-apoptotic genes, and may be earlier in development (pro-NK) with over expression of the CD34 gene. Furthermore, decrease CB vs PB NK cytotoxicity maybe in part secondary to increase programmed cell death in particularly increase NOTCH2 at the genomic and proteomic levels. (The first two authors contribute equally.) No relevant conflicts of interest to declare.
AbstractList Abstract 2781 Umbilical cord blood (UCB) is a viable alternative source of allogeneic hematopoietic stem cells for the treatment of both malignant and non-malignant disease (Cairo et al BBMT 2008). UCB transplantation (UCBT) is known to be associated with decrease severe acute graft-versus-host disease (GvHD) compared to unrelated bone marrow (BM) and peripheral blood (PB) transplantation; however, it is associated with delayed hematopoietic and immune reconstitution (Szabolcs/Cairo et al Seminars in Hematology 2010). NK cells play important roles in both innate and adaptive immunity and are characterized as a CD56+ cell population. NK cell recovery is prompt by 2 months after hematopoietic stem cell transplantation (HSCT), while T-cell (after at least 9 mo HSCT) and B-cell (after 3 to 4 mo HSCT) reconstitutions are gradual and delayed. CD56+dim cells are primarily cytotoxic and make up 90% of PB NK populations (Shereck/Cairo PBC 2007). We previously demonstrated the ability to ex-vivo expand CB MNC into various phenotypes of CD56+dim and CD56+bright NK cells (totally 60%) and NKT cells (40%) with profound in vitro and in vivo cytotoxicity against hematological malignancies (Ayello/Cairo BBMT 2006 & Exp. Hematology 2009). Proteomic studies from our group demonstrated differential protein expression including ↑NKG2A, ↓IP3R type 3, ↓MAPKAPK5, and ↑NOTCH 2 in CB vs PB CD56+dim (Shereck/Cairo, ASH 2007; Shereck/Day/Cairo, ASBMT 2009). In these studies, we sought to determine the similarity or differences in genetic signatures in CB vs APB CD56+dim NK cells. CB MNCs were isolated on a ficoll gradient and NK CD56+16+dim cells isolated using a 2-step magnetic activated cell separation (MACS) process via a standard kit (Miltenyi Biotec). Enrichment was at least 94%. Isolated RNA from CB and PB CD56+dim cells were subjected to microarray studies (Affymetrix, U133A_2) as we have previously described (Jiang/Cairo et al J Immunol 2004). Data were analyzed by Agilent GeneSpring and Ingenuity pathway analyses. Welch test were used to perform statistical analysis and fold change of < 1.5 and values of p<0.05 were considered to be significant. Two-color ECL Plex fluorescence Western blotting (WB) was preformed to validate the proteomic data. Protein samples were separated using SDS-PAGE followed by transblotting. WB membranes were then incubated with target and control (GAPDH) primary antibodies. After rinse and wash, the membranes were further incubated with CY5 and CY3 conjugated secondary antibodies. The membranes were scanned with TYPHOON by green (532 laser and 580 filter) and red (633 laser and 670 filter) setting for CY3 and CY5, respectively, and then observed and quantified using ImageQuant. CB vs PB CD56+dim cells significantly altered expressed 796 genes, in which 486 genes were over expressed, at the genomic level including: pro-apoptotic genes: CASP10 (3.1F), TNFSF11 (4.7F), CDC2 (3.0F), BCL2L1 (4.3F), NOTCH2 (1.5F); and cell development: PBX1 (7.6F), IL1RN (5.1F), CD24 (5.3F), CD34 (3.5F), CD55 (2.1F), CCL13 (2.2F). Conversely, there was significant under expression of NF1 (5.1F), MAP2K3 (1.7F), PIK3CD (2.1F), BAX (2.9F), and JUN (2.2F). Our WB results indicate that NOTCH2 (2.4F) and PBX1 (2.2F) proteins are increased in CB vs PB CD56+dim NK cells, consistent with our proteomic results. These results suggest that CB vs PB CD56+dim NK are more prone to undergo programmed cell death (apoptosis) secondary to over expression of numerous pro-apoptotic genes, and may be earlier in development (pro-NK) with over expression of the CD34 gene. Furthermore, decrease CB vs PB NK cytotoxicity maybe in part secondary to increase programmed cell death in particularly increase NOTCH2 at the genomic and proteomic levels. (The first two authors contribute equally.) No relevant conflicts of interest to declare.
Abstract Abstract 2781 Background. Umbilical cord blood (UCB) is a viable alternative source of allogeneic hematopoietic stem cells for the treatment of both malignant and non-malignant disease (Cairo et al BBMT 2008). UCB transplantation (UCBT) is known to be associated with decrease severe acute graft-versus-host disease (GvHD) compared to unrelated bone marrow (BM) and peripheral blood (PB) transplantation; however, it is associated with delayed hematopoietic and immune reconstitution (Szabolcs/Cairo et al Seminars in Hematology 2010). NK cells play important roles in both innate and adaptive immunity and are characterized as a CD56+ cell population. NK cell recovery is prompt by 2 months after hematopoietic stem cell transplantation (HSCT), while T-cell (after at least 9 mo HSCT) and B-cell (after 3 to 4 mo HSCT) reconstitutions are gradual and delayed. CD56+dim cells are primarily cytotoxic and make up 90% of PB NK populations (Shereck/Cairo PBC 2007). We previously demonstrated the ability to ex-vivo expand CB MNC into various phenotypes of CD56+dim and CD56+bright NK cells (totally 60%) and NKT cells (40%) with profound in vitro and in vivo cytotoxicity against hematological malignancies (Ayello/Cairo BBMT 2006 & Exp. Hematology 2009). Proteomic studies from our group demonstrated differential protein expression including ↑NKG2A, ↓IP3R type 3, ↓MAPKAPK5, and ↑NOTCH 2 in CB vs PB CD56+dim (Shereck/Cairo, ASH 2007; Shereck/Day/Cairo, ASBMT 2009). Objective. In these studies, we sought to determine the similarity or differences in genetic signatures in CB vs APB CD56+dim NK cells. Methods. CB MNCs were isolated on a ficoll gradient and NK CD56+16+dim cells isolated using a 2-step magnetic activated cell separation (MACS) process via a standard kit (Miltenyi Biotec). Enrichment was at least 94%. Isolated RNA from CB and PB CD56+dim cells were subjected to microarray studies (Affymetrix, U133A_2) as we have previously described (Jiang/Cairo et al J Immunol 2004). Data were analyzed by Agilent GeneSpring and Ingenuity pathway analyses. Welch test were used to perform statistical analysis and fold change of < 1.5 and values of p<0.05 were considered to be significant. Two-color ECL Plex fluorescence Western blotting (WB) was preformed to validate the proteomic data. Protein samples were separated using SDS-PAGE followed by transblotting. WB membranes were then incubated with target and control (GAPDH) primary antibodies. After rinse and wash, the membranes were further incubated with CY5 and CY3 conjugated secondary antibodies. The membranes were scanned with TYPHOON by green (532 laser and 580 filter) and red (633 laser and 670 filter) setting for CY3 and CY5, respectively, and then observed and quantified using ImageQuant. Results. CB vs PB CD56+dim cells significantly altered expressed 796 genes, in which 486 genes were over expressed, at the genomic level including: pro-apoptotic genes: CASP10 (3.1F), TNFSF11 (4.7F), CDC2 (3.0F), BCL2L1 (4.3F), NOTCH2 (1.5F); and cell development: PBX1 (7.6F), IL1RN (5.1F), CD24 (5.3F), CD34 (3.5F), CD55 (2.1F), CCL13 (2.2F). Conversely, there was significant under expression of NF1 (5.1F), MAP2K3 (1.7F), PIK3CD (2.1F), BAX (2.9F), and JUN (2.2F). Our WB results indicate that NOTCH2 (2.4F) and PBX1 (2.2F) proteins are increased in CB vs PB CD56+dim NK cells, consistent with our proteomic results. Conclusion. These results suggest that CB vs PB CD56+dim NK are more prone to undergo programmed cell death (apoptosis) secondary to over expression of numerous pro-apoptotic genes, and may be earlier in development (pro-NK) with over expression of the CD34 gene. Furthermore, decrease CB vs PB NK cytotoxicity maybe in part secondary to increase programmed cell death in particularly increase NOTCH2 at the genomic and proteomic levels. (The first two authors contribute equally.) Disclosures: No relevant conflicts of interest to declare.
Author Shereck, Evan
Ayello, Janet
van de Ven, Carmella
Wapner, Ronald J
McGuinn, Catherine
Atallah, Juliana
Cairo, Mitchell S.
Day, Nancy S
Satwani, Prakash
Lim, Megan S.
Author_xml – sequence: 1
  givenname: Nancy S
  surname: Day
  fullname: Day, Nancy S
  organization: Pediatrics, Columbia University, NewYork-Presbyterian, Morgan Stanley Children's Hospital, New York, NY, USA
– sequence: 2
  givenname: Evan
  surname: Shereck
  fullname: Shereck, Evan
  organization: Pediatric Oncology/Hematology, British Columbia Children's Hospital, Vancouver, BC, Canada
– sequence: 3
  givenname: Janet
  surname: Ayello
  fullname: Ayello, Janet
  organization: Pediatrics, Columbia University, NewYork-Presbyterian, Morgan Stanley Children's Hospital, New York, NY, USA
– sequence: 4
  givenname: Catherine
  surname: McGuinn
  fullname: McGuinn, Catherine
  organization: Pediatrics, Columbia University, NewYork-Presbyterian, Morgan Stanley Children's Hospital, New York, NY, USA
– sequence: 5
  givenname: Prakash
  surname: Satwani
  fullname: Satwani, Prakash
  organization: Pediatrics, Columbia University, NewYork-Presbyterian, Morgan Stanley Children's Hospital, New York, NY, USA
– sequence: 6
  givenname: Juliana
  surname: Atallah
  fullname: Atallah, Juliana
  organization: Pediatrics, Columbia University, NewYork-Presbyterian, Morgan Stanley Children's Hospital, New York, NY, USA
– sequence: 7
  givenname: Carmella
  surname: van de Ven
  fullname: van de Ven, Carmella
  organization: Pediatrics, Columbia University, NewYork-Presbyterian, Morgan Stanley Children's Hospital, New York, NY, USA
– sequence: 8
  givenname: Ronald J
  surname: Wapner
  fullname: Wapner, Ronald J
  organization: Obstetrics/Gynecology, Morgan Stanley Children's Hospital of New-York Presbyterian, Columbia University, New York, NY, USA
– sequence: 9
  givenname: Megan S.
  surname: Lim
  fullname: Lim, Megan S.
  organization: Department of Pathology, The University of Michigan, Ann Arbor, MI, USA
– sequence: 10
  givenname: Mitchell S.
  surname: Cairo
  fullname: Cairo, Mitchell S.
  organization: Pediatrics, Medicine, Pathology and Cell Biology, Columbia University, NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA
BookMark eNqFkMtOwzAQRS1UJMrjG_AShBJsx3mUHU2hVCCoxGNrJfYYjFK7skMFv8OXkqTsWLCYO7LG94x999HIOgsIHVMSU1qw87pxTsUvlGYxozHLi63soDFNWRERwsgIjQkhWcQnOd1D-yG8E0J5wtIx-p4ZrcGDbU3V4DlYtzISV1bhpXctDKdH82qr9sNDwAuLS-cVnvZL8Uk5PcUvAS_Bm_Ub-I7wO1h2g3KWZmczs8L3t7iEpgkX-GEDHl99rjtUMM5ip7tbCR-w04E0_Ws7RLu6agIc_fYD9Hx99VTeRHcP80V5eRdJSjIa6UqrjCU643WqKOhcS0KriQbZF4ckqdMir0lRpFmueMWV7H5OUsYk52mhkgOUb7nSuxA8aLH2ZlX5L0GJ6KMWQ9Sij1owKvqUB-mcl1sndM_bGPAiSANWgjIeZCuUM_8yfgDC6Ihl
ContentType Journal Article
Copyright 2010 American Society of Hematology
Copyright_xml – notice: 2010 American Society of Hematology
DBID 6I.
AAFTH
AAYXX
CITATION
DOI 10.1182/blood.V116.21.2781.2781
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
DatabaseTitle CrossRef
DatabaseTitleList
CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
Anatomy & Physiology
EISSN 1528-0020
EndPage 2781
ExternalDocumentID 10_1182_blood_V116_21_2781_2781
S0006497119448489
GroupedDBID ---
-~X
.55
1CY
23N
2WC
34G
39C
4.4
53G
5GY
5RE
5VS
6I.
6J9
9M8
AAEDW
AAFTH
AAXUO
ABOCM
ABVKL
ACGFO
ADBBV
AENEX
AFFNX
AFOSN
AHPSJ
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
EX3
F5P
FDB
FRP
GS5
GX1
IH2
K-O
KQ8
L7B
LSO
MJL
N4W
N9A
OK1
P2P
R.V
RHF
RHI
ROL
SJN
THE
TR2
TWZ
W2D
W8F
WH7
WOQ
WOW
X7M
YHG
YKV
ZA5
0R~
0SF
AALRI
AAYXX
ADVLN
AITUG
AKRWK
AMRAJ
CITATION
H13
ID FETCH-LOGICAL-c1061-fafd623f64b5d1ef7fc01a9fec9fec4e33b587b088567d4a4dcffe0522c4458d3
IEDL.DBID ABVKL
ISSN 0006-4971
IngestDate Fri Aug 23 00:28:05 EDT 2024
Fri Feb 23 02:43:41 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 21
Language English
License This article is made available under the Elsevier license.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1061-fafd623f64b5d1ef7fc01a9fec9fec4e33b587b088567d4a4dcffe0522c4458d3
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0006497119448489
PageCount 1
ParticipantIDs crossref_primary_10_1182_blood_V116_21_2781_2781
elsevier_sciencedirect_doi_10_1182_blood_V116_21_2781_2781
PublicationCentury 2000
PublicationDate 2010-11-19
PublicationDateYYYYMMDD 2010-11-19
PublicationDate_xml – month: 11
  year: 2010
  text: 2010-11-19
  day: 19
PublicationDecade 2010
PublicationTitle Blood
PublicationYear 2010
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
SSID ssj0014325
Score 2.0280063
Snippet Abstract 2781 Umbilical cord blood (UCB) is a viable alternative source of allogeneic hematopoietic stem cells for the treatment of both malignant and...
Abstract Abstract 2781 Background. Umbilical cord blood (UCB) is a viable alternative source of allogeneic hematopoietic stem cells for the treatment of both...
SourceID crossref
elsevier
SourceType Aggregation Database
Publisher
StartPage 2781
Title Differential Genomic and Proteomic Signatures In Cord Blood (CB) Vs Peripheral Blood (PB) CD56+Dim NK Cells: Over Expression of CD34 In CB Vs PB CD56+Dim NK Cells
URI https://dx.doi.org/10.1182/blood.V116.21.2781.2781
Volume 116
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LbtQwcNRuxeNSwRZEoa18QAgO6a5jO7Z726QthaVlEXTVW5Q4Nlppm1ZskeB3-NKOHQeBQOLAIVYSZ6w4M55HPA-A5y7VyPYbm2TG6oQ7LRKVKZZoVjVoNdeOGR_gfHqWnZzztxfiYg2KPhbGu1VG3t_x9MCt451R_Jqj68XCx_iiONWSohnOFVd6HTZSmY3TAWxM8vn03c_NBM7SrpABGs8eILp5oWY9Ct7h-3NKs_0UrUWpuubvQuoXwXP8ADajxkgm3Us9hDXbDmFr0qK1fPmdvCDBhzP8HB_Cnbw_u1f0ldyGcPc0bqBvwY_DWBAFF_aSvLYhKJlUbUNmPmFDuPq4-Nyl-1yRNy0p0DoluZ8AeVnkr8h8RWZItSEbwbLvmGFHcSiQiBaX5GxKCrtcrg7Ie1wn5Ohb9LVtyZXDpxgPw-ZhpPxPsEdwfnz0qThJYpmGxHh7MnGVa1CJchmvRUOtk86MaaWdNf7glrFaKFkjOxOZbHjFG4MzHaPiZzgXqmGPYdBetfYJEEVdTaUyda0oN1LoTDruqJCsckIbvg3jHi_ldZeNowxWjErLgMrSo7JMaemxGJptOOjxV_5GWCXKjH8BP_0f4GdwP7gaeJ9BvQODmy9f7S5qMDf1XqTQPVifflC3oDDphQ
link.rule.ids 315,786,790,27602,27957,27958,45698
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LbtQwcFS2gvaCYAui5eUDQnBId53Ysd3bJm3Zsg9Wol31FiWOjVbaphVbJPgdvpSx4yAQSBw4xErijBVnxvOI5wHwysYK2X5tolQbFTGreCRTmUQqKWu0miubaBfgPJun4wv2_pJfbkHexcI4t8rA-1ue7rl1uDMIX3Nws1q5GF8Up0pQNMOZZFLdgW3UBpTswfYoW06mPzcTWBK3hQzQeHYAwc0LNeuB9w4_XFKaHsZoLQrZNn8XUr8IntMHcD9ojGTUvtRD2DJNH_ZGDVrLV9_Ia-J9OP3P8T7czbqznbyr5NaHe7Owgb4H349DQRRc2GvyzvigZFI2NVm4hA3-6uPqU5vuc0POGpKjdUoyNwHyJs_ekuWGLJBqfTaCddexwI78mCMRra7IfEJys15vjsgHXCfk5GvwtW3ItcWnEuaHzfxI2Z9gj-Di9OQ8H0ehTEOknT0Z2dLWqETZlFW8psYKq4e0VNZodzCTJBWXokJ2xlNRs5LVGmc6RMVPM8ZlnTyGXnPdmCdAJLUVFVJXlaRMC65SYZmlXCSl5UqzfRh2eClu2mwchbdiZFx4VBYOlUVMC4dF3-zDUYe_4jfCKlBm_Av44H-AX8LO-Hw2LaZn88lT2PVuB85_UD2D3u3nL-Y5ajO31YtArT8AWd3riQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differential+Genomic+and+Proteomic+Signatures+In+Cord+Blood+%28CB%29+Vs+Peripheral+Blood+%28PB%29+CD56%2BDim+NK+Cells%3A+Over+Expression+of+CD34+In+CB+Vs+PB+CD56%2BDim+NK+Cells&rft.jtitle=Blood&rft.au=Day%2C+Nancy+S&rft.au=Shereck%2C+Evan&rft.au=Ayello%2C+Janet&rft.au=McGuinn%2C+Catherine&rft.date=2010-11-19&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=116&rft.issue=21&rft.spage=2781&rft.epage=2781&rft_id=info:doi/10.1182%2Fblood.V116.21.2781.2781&rft.externalDBID=n%2Fa&rft.externalDocID=10_1182_blood_V116_21_2781_2781
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon